Patent · US Active

Combination of regorafenib and acetylsalicylic acid for treating cancer

US10898500B2 · kind B2 · utility

0Cited by

3References

4Claims

0Family size

Assignees

Bayer Pharma Aktiengesellschaft · DE
BAYER HEALTHCARE LLC · DE

Inventors

Olaf Weber · Wülfrath, DE
Karl Ziegelbauer · Wuppertal, DE

Key dates

Filing date	Sep 23, 2013
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Sep 23, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.